Gunther Boysen
Astellas Pharma (United Kingdom)(GB)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Cancer Genomics and Diagnostics, Cancer, Lipids, and Metabolism, PARP inhibition in cancer therapy, Renal cell carcinoma treatment
Most-Cited Works
- → DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer(2015)2,165 cited
- → Punctuated Evolution of Prostate Cancer Genomes(2013)1,340 cited
- → Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition(2017)415 cited
- → DNA Repair in Prostate Cancer: Biology and Clinical Implications(2016)232 cited
- → Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer(2019)227 cited
- → Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer(2018)205 cited
- → SPOP mutation leads to genomic instability in prostate cancer(2015)192 cited
- → Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)(2018)151 cited
- → SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity(2018)139 cited
- → Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer(2012)125 cited